Omega Therapeutics, Inc.
DelistedCIK 1850838fmd_1M2RHP8SK2JBKF13J5GS6WW5PEManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2024, 19 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|
| Total revenues | – | 0 | 2 | 3 |
| Net interest income | – | (1) | 0 | 3 |
| Research and development | 21 | 48 | 81 | 77 |
| Total operating expenses | 29 | 66 | 105 | 103 |
| Operating income | (29) | (66) | (103) | (100) |
| Interest expense | 1 | 1 | 1 | 2 |
| Other non-operating income (expense) | (1) | (2) | 0 | 3 |
| Income tax expense | 0 | 0 | 0 | 0 |
| Net income | (29) | (68) | (103) | (97) |